Home    Back

Eicosapentaenoic acid    (DrugBank: Eicosapentaenoic acid)

5 diseases
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus1
96Crohn disease1
97Ulcerative colitis2
296Biliary atresia1
297Alagille syndrome1

49. Systemic lupus erythematosus    [ 827 clinical trials,   638 drugs,   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways]
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 827 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2004-004404-21-GB
(EUCTR)		10/12/200417/02/2005Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in LupusOmega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus Systemic Lupus ErythematosusTrade Name: Omacor
Product Name: Omacor
INN or Proposed INN: Eicosapentaenoic acid
INN or Proposed INN: Docosahexaenoic acid
INN or Proposed INN: alpha-tocopherol		GreenPark Healthcare TrustQueens University BelfastNot RecruitingFemale: yes
Male: yes		60Phase 4United Kingdom

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,209 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02179372
(ClinicalTrials.gov)		June 201429/6/2014Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel DiseasesModulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel DiseasesUlcerative Colitis;Crohn's DiseaseDietary Supplement: Eicosapentaenoic acid;Dietary Supplement: Medium chain fatty acid (placebo)Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola MalpighiNULLCompleted18 Years80 YearsBoth60N/AItaly

97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,269 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02179372
(ClinicalTrials.gov)		June 201429/6/2014Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel DiseasesModulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel DiseasesUlcerative Colitis;Crohn's DiseaseDietary Supplement: Eicosapentaenoic acid;Dietary Supplement: Medium chain fatty acid (placebo)Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola MalpighiNULLCompleted18 Years80 YearsBoth60N/AItaly
2NCT02069561
(ClinicalTrials.gov)		January 201419/2/2014Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal CancerEffects of Eicosapentaenoic Acid on Molecular, Metabonomics and Intestinal Microbiota Changes, in Subjects With Long-standing Inflammatory Bowel DiseaseUlcerative ColitisDietary Supplement: Eicosapentaenoic AcidAzienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola MalpighiNULLCompleted18 Years70 YearsBoth25N/AItaly

296. Biliary atresia    [ 53 clinical trials,   56 drugs,   (DrugBank: 31 drugs),   43 drug target genes,   50 drug target pathways]
Searched query = "Biliary atresia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 53 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-jRCTs041180088
01/12/201612/03/2019Influence of fatty acid metabolism for clinical course of biliary atresiaThe difference of the profile of fatty acids and eicosanoids in clinical course and the effect to the prognosis by collection of biliary atresia biliary atresia, neonatal hepatitis, Alagille syndrome, PFIC, etc.oral administration of 30(+/- 10)mg/kg/day of eicosapentaenoic acidSumida WataruUchida HirooRecruitingNot applicableNot applicableBoth30N/AJapan

297. Alagille syndrome    [ 26 clinical trials,   16 drugs,   (DrugBank: 8 drugs),   2 drug target genes,   2 drug target pathways]
Searched query = "Alagille syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 26 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-jRCTs041180088
01/12/201612/03/2019Influence of fatty acid metabolism for clinical course of biliary atresiaThe difference of the profile of fatty acids and eicosanoids in clinical course and the effect to the prognosis by collection of biliary atresia biliary atresia, neonatal hepatitis, Alagille syndrome, PFIC, etc.oral administration of 30(+/- 10)mg/kg/day of eicosapentaenoic acidSumida WataruUchida HirooRecruitingNot applicableNot applicableBoth30N/AJapan

Back to top